Medicine:Methoxyetomidate
From HandWiki
Methoxyetomidate is an investigational anesthetic agent being developed by Jinzhou Ahon Pharmaceutical Co., Ltd. It is a short-acting intravenous anesthetic that acts as a positive allosteric modulator of GABAA receptors.[1][2] As of 2024, methoxyetomidate is undergoing Phase 3 clinical trials for use in anesthesia.[3][1]
References
- ↑ 1.0 1.1 "ET-26 Methoxyetomidate Hydrochloride Development Information". https://synapse.patsnap.com/organization/98d472811331dcaffa6e0413f889cf3b.
- ↑ "ET-26 hydrochloride (ET-26 HCl) has similar hemodynamic stability to that of etomidate in normal and uncontrolled hemorrhagic shock (UHS) rats". PLOS ONE 12 (8). 2017. doi:10.1371/journal.pone.0183439. PMID 28813523. Bibcode: 2017PLoSO..1283439W.
- ↑ "ET-26 Clinical Trials Overview". https://synapse.patsnap.com/drug/8c966c5f7604453ca1fa4b216a866308.
 |  |
